Login to Your Account

Milestone for Array; Astrazeneca Starts Phase III NSCLC Trial

By Peter Winter
BioWorld Insight Editor

Tuesday, October 22, 2013

Boulder, Colo.-based Array Biopharma Inc. will be receiving a $5 million milestone payment following the announcement that Astrazeneca plc has begun a Phase III trial for selumetinib, an oral MEK inhibitor.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription